Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISTARIL vs HYDROXYZINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.
Anxiety and tension associated with psychoneurosis,Pruritus due to allergic conditions (e.g., urticaria, atopic dermatitis),Sedation prior to dental or surgical procedures,Nausea and vomiting (off-label)
Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitis,Anxiety and tension (as a short-term management in adults),Preoperative sedation and to reduce anxiety prior to surgery,Nausea and vomiting (off-label),Insomnia (off-label)
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites include cetirizine.
No specific adjustment; use with caution in severe renal impairment due to potential accumulation of metabolites.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: administer every 24 hours. Not recommended for use in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) due to increased risk of neurotoxicity.
No FDA black box warning.
First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal withdrawal symptoms (irritability, tremors) with chronic maternal use near term; no evidence of structural anomalies.
Hydroxyzine is generally considered low risk for teratogenicity. Animal studies have shown no consistent evidence of fetal harm. Human data are limited but do not indicate a significant increase in major malformations. In the first trimester, use only if clearly needed. In the second and third trimesters, there is a potential risk of neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term or in high doses. Avoid use during labor and delivery due to potential maternal hypotension and fetal effects.
VISTARIL (hydroxyzine pamoate) is a first-generation antihistamine with anxiolytic and sedative properties. It is often used for preoperative sedation, pruritus, and anxiety. Onset of sedation is rapid (15-30 minutes) but duration is short (4-6 hours). It has anticholinergic effects; caution in elderly and patients with glaucoma or prostatic hypertrophy. Do not administer intra-arterially or subcutaneously (risk of hemolysis or tissue necrosis). It is not a controlled substance, but has abuse potential. May cause significant somnolence; advise against driving or operating machinery.
Hydroxyzine is a first-generation antihistamine with anxiolytic, sedative, and antiemetic properties. It is commonly used for pruritus, anxiety, and premedication. Avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, risk of confusion and falls is increased; consider alternative therapies. Hydroxyzine has anticholinergic effects; use cautiously in patients with glaucoma, urinary retention, or prostatic hyperplasia. Note that hydroxyzine can cause QT prolongation at high doses or in combination with other QT-prolonging drugs.
No interactions on record
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Hydroxyzine."
"Diphenoxylate, an opioid agonist, enhances the central nervous system (CNS) depressant effects of hydroxyzine, a first-generation antihistamine with sedative properties. This synergistic interaction results in additive sedation, respiratory depression, and impaired psychomotor function, increasing the risk of excessive drowsiness, dizziness, and potentially life-threatening respiratory compromise. Patients may experience heightened confusion, ataxia, and reduced ability to perform tasks requiring alertness, necessitating cautious dose adjustment or alternative therapy."
"Flunarizine, a calcium channel blocker with antihistaminergic properties, potentiates the central nervous system (CNS) depressant effects of hydroxyzine, a first-generation antihistamine. This additive pharmacodynamic interaction can lead to excessive sedation, dizziness, cognitive impairment, and increased risk of falls, particularly in elderly patients. Clinically, patients may experience heightened drowsiness, psychomotor slowing, and impaired coordination, requiring dose adjustments or alternative therapies."
VISTARIL and HYDROXYZINE are distinct pharmacological agents. VISTARIL belongs to the Antihistamine class and is primarily used for Anxiety and tension associated with psychoneurosisPruritus due to allergic conditions (e.g., urticaria, atopic dermatitis)Sedation prior to dental or surgical proceduresNausea and vomiting (off-label). HYDROXYZINE belongs to the Antihistamine class and is primarily used for Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitisAnxiety and tension (as a short-term management in adults)Preoperative sedation and to reduce anxiety prior to surgeryNausea and vomiting (off-label)Insomnia (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VISTARIL carries a safety status of Category C, whereas HYDROXYZINE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hydroxyzine is primarily metabolized by the liver via CYP3A4 and CYP2D6 isoenzymes. The major active metabolite is cetirizine, which is also a histamine H1 receptor antagonist.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.
Highly protein-bound: approximately 89-93%, primarily to albumin.
93% bound to plasma proteins, primarily albumin.
Volume of distribution: 7-10 L/kg, indicating extensive tissue distribution.
16 L/kg (range 7-20 L/kg), indicating extensive tissue distribution; higher Vd suggests large extravascular binding.
Oral: incomplete bioavailability due to first-pass metabolism, estimated at 40-60%; IM: nearly complete (85-100%).
Oral: approximately 80%; IM: >80% (almost complete and rapid); IV: 100%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class B: reduce dose by 50% and/or increase dosing interval to every 12-24 hours. Child-Pugh Class C: use with caution; consider alternative agent or reduce dose by 75% and administer every 24 hours.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 50 mg per dose (≤12 years); IM: 0.5-1 mg/kg every 4-6 hours.
Oral: 2 mg/kg/day in divided doses every 6-8 hours. Maximum: 50 mg/day for children <6 years; 100 mg/day for 6-12 years. IM: 0.5-1 mg/kg every 6-8 hours, not to exceed 50 mg per dose.
Start at lower end of dosing range (e.g., 25 mg oral 3-4 times daily); monitor for sedation and anticholinergic effects.
Initiate at lowest dose (25 mg orally 3-4 times daily) and titrate cautiously due to increased risk of sedation, confusion, and anticholinergic effects. Maximum recommended dose: 100 mg/day in divided doses.
There is no FDA black box warning for hydroxyzine.
Alcohol increases sedation and CNS depression; avoid concurrent use. No significant food interactions, but take with food if GI upset occurs.
Hydroxyzine may be taken with or without food. Grapefruit juice may increase hydroxyzine serum concentrations and risk of adverse effects; avoid concurrent consumption. High-fat meals can delay but not significantly reduce absorption. No other food restrictions are required.
Hydroxyzine is excreted in human milk; M/P ratio not established. Potential for adverse effects in infants (sedation, irritability). Use during breastfeeding only if clearly needed; monitor infant for drowsiness.
Hydroxyzine is excreted into breast milk in small amounts. The milk-to-plasma ratio is estimated at approximately 0.5. In infants, it may cause sedation, irritability, or poor feeding. Because of the potential for serious adverse reactions in nursing infants, consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for hydroxyzine and any potential adverse effects on the breastfed infant. Alternatives with better safety profiles may be preferred.
No specific dose adjustments recommended in pregnancy; use lowest effective dose. Hydroxyzine may be less effective if used as an antiemetic due to altered clearance; consider alternative agents.
Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma albumin, and altered hepatic metabolism) may affect hydroxyzine concentrations. However, specific dose adjustments for pregnancy are not well-established. Clinical monitoring for efficacy and adverse effects is recommended, and using the lowest effective dose for the shortest duration is prudent. No routine dose adjustment is mandated, but individual patient response should guide therapy.
Take as prescribed; do not exceed recommended dose.,May cause drowsiness; avoid driving or heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of allergic reaction (rash, difficulty breathing) immediately.,Do not stop abruptly without consulting doctor.,Store at room temperature away from moisture and heat.
Take hydroxyzine exactly as prescribed and do not exceed the recommended dose.,Avoid driving or operating heavy machinery until you know how hydroxyzine affects you, as it may cause drowsiness or dizziness.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) while taking hydroxyzine.,Notify your doctor if you experience blurred vision, dry mouth, difficulty urinating, or rapid heartbeat.,Do not stop taking hydroxyzine abruptly if using for anxiety; consult your doctor for a taper plan.,Store at room temperature, away from moisture and heat.